Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Aflibercept + Capecitabine |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Aflibercept | Zaltrap | AVE 0005|Eylea|Ziv-Aflibercept | VEGF Antibody 17 VEGFR Inhibitor (Pan) 36 | Zaltrap (aflibercept) is comprised of human IgG fused to the extracellular domains of VEGFR1 and VEGFR2, which binds VEGF to inhibit tumor angiogenesis and metastasis. Zaltrap (aflibercept) is FDA approved in patients with metastatic colorectal cancer (FDA.gov). |
| Capecitabine | Xeloda | R340|Ro 09-1978/000 | Chemotherapy - Antimetabolite 14 | Xeloda (capecitabine) is a prodrug that is converted to 5-FU, ultimately inhibiting RNA and DNA synthesis and cell division (PMID: 28520372). Xeloda (capecitabine) is FDA-approved for use in patients with colorectal, breast, gastric, esophageal, gastroesophageal junction, and pancreatic cancer (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01661972 | Phase Ib/II | Aflibercept + Capecitabine | Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer | Completed | USA | 0 |